VR Logo

Vor Biopharma Inc. (VOR) download report


Healthcare | Biotechnology & Pharma Research

Vor Biopharma Inc. (VOR) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.

IPO Date: 05-Feb-2021

Pres, CEO & Director: Dr. Robert Ang M.B.A., M.D., MBBS

Chief Scientific Officer: Dr. Tirtha Chakraborty Ph.D.

Listing: NASDAQ: VOR

Country: United States

Headquarters: Cambridge, MA

Website: https://www.vorbio.com

Key Facts

Market cap: $209.42 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-77.91 Mln

Cash: $181.62 Mln

Total Debt: $28.96 Mln

Insider's Holding: 10.65%

Liquidity: Low

52 Week range: $3.85 - 20.90

Shares outstanding: 37,598,400

Stock Performance

Time Period Vor Biopharma (VOR) S&P BSE Sensex S&P Small-Cap 600
YTD-55.55-8.99-19.23
1 month22.39-3.40-9.35
3 months-19.67-8.50-16.59
1 Year-73.550.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022